Dernières nouvelles pour US Foods Hldg (NYSE:USFD) Stock

US Foods Hldg

Tyme Technologies

US Foods Holding Corp is the U.S. food service distributor. us Foods distributes food and nonfood products to the healthcare and hospitality industries, restaurants, and education, government facilities, and grocers. In addition to its delivery business, the firm has 80 cash-and- carry stores under the Chef'Store banner. The company generates majority of the revenue from Meats and seafood products.

US Foods Holding Corp

US FOODS ORD

Hovde Group initiates coverage on Horizon Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBNC#NASDAQ">HBNC</a>) with a Outperform rating and announces Price Target of $18.

News

Price Target

Initiation

Analyst Ratings

HBNC

Hovde Group Initiates Coverage On Horizon Bancorp with Outperform Rating, Announces Price Target of $18

Amgen's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NYSE">AMGN</a>) short percent of float has risen 6.33% since its last report. The company recently reported that it has 9.00 million shares sold short, which is 1.68% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.19 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Amgen Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727717425_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Amgen has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Amgen's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Amgen's peer group average for short interest as a percentage of float is 5.95%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

AMGN

(AMGN) - Analyzing Amgen's Short Interest

Nano Labs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NA#NYSE">NA</a>) short percent of float has fallen 13.33% since its last report. The company recently reported that it has 41 thousand shares sold short, which is 0.13% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Nano Labs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727717419_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Nano Labs has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Nano Labs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Nano Labs's peer group average for short interest as a percentage of float is 5.74%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(NA) - Analyzing Nano Labs's Short Interest

Canadian Natural Res (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNQ#NYSE">CNQ</a>) has outperformed the market over the past 20 years by 1.4% on an annualized basis producing an average annual return of 9.82%. Currently, Canadian Natural Res has a market capitalization of $70.72 billion. 
Buying $1000 In CNQ: If an investor had bought $1000 of CNQ stock 20 years ago, it would be worth $6,422.83 today based on a price of $33.24 for CNQ at the time of writing.
<h3>Canadian Natural Res's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727717417_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Canadian Natural Res 20 Years Ago Would Be Worth This Much Today

SolarEdge Technologies's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NYSE">SEDG</a>) short percent of float has risen 8.62% since its last report. The company recently reported that it has 18.74 million shares sold short, which is 39.19% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.03 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>SolarEdge Technologies Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727717414_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for SolarEdge Technologies has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing SolarEdge Technologies's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, SolarEdge Technologies's peer group average for short interest as a percentage of float is 5.31%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

SEDG

(SEDG) - Analyzing SolarEdge Technologies's Short Interest

DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) has outperformed the market over the past 15 years by 14.45% on an annualized basis producing an average annual return of 26.36%. Currently, DexCom has a market capitalization of $27.15 billion. 
Buying $100 In DXCM: If an investor had bought $100 of DXCM stock 15 years ago, it would be worth $3,262.77 today based on a price of $67.76 for DXCM at the time of writing.
<h3>DexCom's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727717412_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DXCM

$100 Invested In DexCom 15 Years Ago Would Be Worth This Much Today

Macro Economic Events

Global

Economics

iShares MSCI Israel Capped Investable Market Index Fund

ISRA

U.S. State Department Says Israel Has Told Us About A Number Of Operations But Those Are Limited Operations Focused On Hezbollah Infrastructure Near The Border With Lebanon

Evercore ISI Group analyst Stephen Richardson maintains Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) with a In-Line and lowers the price target from $55 to $50.

Evercore ISI Group Maintains In-Line on Devon Energy, Lowers Price Target to $50

Longer-Term Commitment to Resiliency and Investment Beyond the near-term actions of GHRI Phase Two, CenterPoint will refile its long-term resiliency plan with the PUCT on or before January 31, 2025. The goal of the long-term resiliency plan is to mitigate a broad spectrum of risks that threaten its system by hardening key aspects of the infrastructure, enhancing the security of the grid and building a smarter grid that can combat extreme weather, major storms and hurricanes to reduce the impact of outages experienced by its customers and mitigate wildfire risk.
As part of the long-term plan, CenterPoint will also propose investing at least $5 billion from 2026 to 2028 – the largest investment in Greater Houston infrastructure in the company's nearly 160-year history. The at least $5 billion is part of CenterPoint's new capital investment plan that includes more than $21 billion in total capital investment in its Texas electric and gas systems from 2025 through 2030, exceeding its current plan.

Guidance

CenterPoint Energy Announces A Comprehensive Suite of New Actions Of Greater Houston Resiliency Initiative To Strengthen The Electric Grid Across The Region; Beyond Near-Term Actions Of GHRI Phase Two, Co Will Refile Its Long-Term Resiliency Plan With PUCT On Or Before January 31, 2025; Co Will Also Propose Investing At Least $5B From 2026-2028

In a stark contrast to Sam Bankman-Fried&#8216;s assertions last January, <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41084342/ftx-token-stuns-market-with-60-gains-whats-going-on-with-crypto-of-the-bankrupt-exchange-f">recent developments suggest FTX</a> customers face a long wait for potential repayments.
What Happened: TV host Ran Neuner has shed light on the protracted timeline for FTX distributions, which are now expected to extend well into 2024 and possibly 2025.
<a href="https://x.com/cryptomanran/status/1840415403933360283">According</a> to Neuner, a crucial court hearing is scheduled for Oct. 7 to confirm FTX&#8217;s Chapter 11 reorganization plan.
If approved, this will set the stage for repayments to begin. 
However, distributions would only start within 60 days of the plan becoming effective, and initially only for claimants owed less than $50,000. 
Larger claimants may not see distributions until Q1 2025 at the earliest.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/27091545/Benzinga-conference.gif" alt="Benzinga future of digital assets conference" class="wp-image-267246" /></a></figure>
Also Read: <a href="https://www.benzinga.com/24/09/41075742/mark-cuban-as-treasury-secretary-no-head-of-the-sec-is-the-job-hed-take-because-gary-gensler-has-bee">Mark Cuban As Treasury Secretary? No, &#8216;Head Of The SEC&#8217; Is The Job He&#8217;d Take Because Gary Gensler Has Been &#8216;Awful&#8217; For Crypto, Businesses</a>
Why It Matters: This timeline stands in sharp relief to the statements made by Bankman-Fried in January 2023, just days <a href="https://www.benzinga.com/markets/cryptocurrency/23/01/30393494/top-4-craziest-things-sam-bankman-fried-laid-bare-in-his-new-substack">after his release on a $250 million bond</a>.
At that time, the former FTX CEO took to social media to deny allegations of misappropriating user funds and criticize Binance CEO Changpeng Zhao for an alleged campaign against his exchange.
&#8220;I didn&#8217;t steal funds, and I certainly didn&#8217;t stash billions away,&#8221; Bankman-Fried had claimed, asserting that the majority of his possessions were still being used to support FTX&#8217;s customers. 
He also stated that both FTX International and Alameda were &#8220;legitimately and independently profitable businesses in 2021, each making billions.&#8221;
Bankman-Fried had further alleged that Alameda fell victim to a &#8220;targeted attack&#8221; after implementing substantial hedges, which ultimately led to FTX&#8217;s downfall. 
He expressed frustration that FTX US users hadn&#8217;t been &#8220;made whole,&#8221; claiming the entity had $350 million in net cash when he departed.
Now, as the repayment process stretches into the future, these past claims serve as a reminder of the complex and often contentious nature of cryptocurrency bankruptcies. 
The extended timeline for customer repayments underscores the challenges in resolving such high-profile collapses in the crypto industry.
What&#8217;s Next: This ongoing saga is likely to be a focal point at Benzinga&#8217;s <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19, where industry experts may dissect the FTX case, its implications for regulatory frameworks and the future of customer protection in the crypto space.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41072097/viral-baby-hippo-moo-deng-steals-spotlight-from-dogecoin-shiba-inu-this-trader-made-392-00">Viral Baby Hippo Moo Deng Steals Spotlight From Dogecoin, Shiba Inu: This Trader Made $392,000 With Over 1,000X Meme Coin Return</a></li>
</ul>
Some elements of this story were previously reported by Benzinga and it has been updated.
Image created using artificial intelligence with Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Remember SBF's 'I Didn't Stash Billions Away'? The Latest FTX Repayment Update May Have Other Ideas

CICC analyst Xiaodan Zhang initiates coverage on ZKH Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZKH#NYSE">ZKH</a>) with a Outperform rating and announces Price Target of $4.

CICC Initiates Coverage On ZKH Group with Outperform Rating, Announces Price Target of $4

JP Morgan analyst John Ivankoe maintains Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) with a Overweight and raises the price target from $90 to $105.

SBUX

JP Morgan Maintains Overweight on Starbucks, Raises Price Target to $105

WIIM

NCLH

Shares of cruise stocks are trading lower in sympathy with Carnival, which issued guidance below estimates.

Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Amedisys (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amed#NASDAQ">AMED</a>) and Chemed (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/che#NYSE">CHE</a>). But which of these two stocks presents investors with the better value opportunity right now? Let&#39;s take a closer look.
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.
Amedisys and Chemed are sporting Zacks Ranks of #2 (Buy) and #3 (Hold), respectively, right now. The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that AMED has an improving earnings outlook. But this is only part of the picture for value investors.
Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.
Our Value category highlights undervalued companies by looking at a variety of key metrics, including the popular P/E ratio, as well as the P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that have been used by value investors for years.
AMED currently has a forward P/E ratio of 20.73, while CHE has a forward P/E of 25.41. We also note that AMED has a PEG ratio of 1.89. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company&#39;s expected earnings growth rate. CHE currently has a PEG ratio of 2.26.
Another notable valuation metric for AMED is its P/B ratio of 2.68. Investors use the P/B ratio to look at a stock&#39;s market value versus its book value, which is defined as total assets minus total liabilities. By comparison, CHE has a P/B of 7.47.
These metrics, and several others, help AMED earn a Value grade of B, while CHE has been given a Value grade of C.
AMED stands above CHE thanks to its solid earnings outlook, and based on these valuation figures, we also feel that AMED is the superior value option right now.
<a href="https://www.zacks.com/stock/news/2343525/amed-or-che-which-is-the-better-value-stock-right-now?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_3-2343525">To read this article on Zacks.com click here.</a>

Health Care

Markets

General

AMED

AMED Or CHE: Which Is The Better Value Stock Right Now?

On Friday, the SEC <a target="_blank" href="https://www.sec.gov/enforcement-litigation/administrative-proceedings/34-101202-s" rel="noreferrer noopener">disclosed settling charges</a> against Austin Kauh of Wilton, CT, for insider trading before the December 2021 announcement that Kauh&#8217;s employer, Chewy, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) collaborated with Trupanion, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>).
According to the SEC&#8217;s order, Kauh was part of Chewy&#8217;s due diligence team during the period leading up to the announcement.
In this role, he learned about plans for a partnership that would allow Trupanion to offer an exclusive suite of pet health insurance and wellness plans to more than 20 million Chewy customers.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/insights/news/24/09/41068853/adobe-chair-and-ceo-sold-13-04m-in-company-stock" rel="noreferrer noopener">Adobe Chair and CEO Sold $13.04M In Company Stock</a>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/30124615/newplot-1-8.png" alt="" class="wp-image-572907" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/30124615/newplot-1-8.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/30124615/newplot-1-8-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
Between June 10, 2021, and August 25, 2021, Kauh purchased Trupanion stock using this material nonpublic information in violation of his duties to his employer.&nbsp;
Kauh conducted this trading in his personal account and in an account held in the name of another person.&nbsp;
When Trupanion&#8217;s stock price rose by 39% following the announcement, Kauh generated ill-gotten gains of $4,344 in his account and $12,093 in the other.&nbsp;
The SEC&#8217;s order finds that Kauh violated the SEC&#8217;s antifraud provisions.&nbsp;
Without admitting or denying the SEC&#8217;s findings, Kauh consented to the issuance of a cease-and-desist order and a five-year bar from acting as an officer or director of a public company and agreed to pay disgorgement of $4,344, prejudgment interest of $634.79, and a civil penalty of $30,297.14.
Chewy stock is up over 57% in the last 12 months. Trupanion&nbsp;stock is up over 57%.
Price Action: CHWY stock is down 2.34% at $29.27 at last check Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/insights/news/24/09/41096486/insider-decision-scott-robinson-exercises-options-at-donaldson-for-1-57m" target="_blank" rel="noreferrer noopener">Insider Decision: Scott Robinson Exercises Options At Donaldson For $1.57M</a></li>
</ul>
Photo via Shutterstock.

Government

Regulations

Insider Trades

CHWY

TRUP

Chewy Insider Penalized by SEC for Trading on Confidential Pet Insurance Deal Info

RBC Capital analyst Walter Spracklin maintains Norfolk Southern (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>) with a Outperform and raises the price target from $267 to $272.

RBC Capital Maintains Outperform on Norfolk Southern, Raises Price Target to $272

On Friday, BridgeBio Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>)&nbsp;presented a post-hoc analysis evaluating the effect of acoramidis on the composite endpoint of all-cause mortality (ACM) and recurrent cardiovascular-related hospitalizations (CVH) events in its Phase 3 ATTRibute-CM <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g41077364/bridgebio-shares-recurrent-event-analysis-of-attribute-cm-demonstrating-a-42-reduction-by-acoramid" rel="noreferrer noopener">study in ATTR-CM</a>.
The data were shared at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2024.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40819741/bridgebio-pharma-seeks-partner-to-develop-gene-therapy-for-inherited-condition" rel="noreferrer noopener">BridgeBio Pharma Seeks Partner To Develop Gene Therapy For Inherited Condition</a>.
ATTRibute-CM was designed to evaluate the efficacy and safety of acoramidis.
The analysis included:
<ul>
<li>A 42% reduction in composite ACM and recurrent CVH events at 30 months was observed with acoramidis treatment compared to placebo by applying a negative binomial regression model (post-hoc) (p=0.0005).</li>
<li>A 42% reduction in ACM and recurrent CVH events per patient was observed over 30 months with acoramidis treatment compared to placebo.</li>
<li>A 30.5% hazard reduction in ACM and recurrent CVH events at 30 months was observed with acoramidis treatment compared to placebo by applying the Andersen-Gill model (post-hoc) (p=0.0008).</li>
</ul>
&#8220;This post-hoc analysis provides further evidence that near-complete TTR stabilization with acoramidis can improve clinical outcomes for patients with ATTR-CM. The reduction of hospitalizations and all-cause mortality seen in ATTRibute-CM heightens the case for acoramidis as a first-line therapy, given its potential to improve the overall quality of life for patients,&#8221; said Daniel Judge, M.D., professor of medicine and cardiology at the Medical University of South Carolina.
Transthyretin amyloidosis (ATTR-CM) occurs when the liver produces faulty transthyretin (TTR) proteins. Clumps of these abnormal proteins (fibrils) build up in the heart&#8217;s main pumping chamber.
Based on the results from ATTRibute-CM, BridgeBio submitted an FDA marketing application, which has been accepted with a PDUFA action date of November 29, 2024, and a Marketing Authorization Application to the European Medicines Agency, with a decision expected in 2025.
In August, BridgeBio Pharma presented additional data from an analysis of its Phase 3 ATTRibute-CM and open-label extension study of acoramidis in ATTR-CM at the European&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40658278/why-is-bridgebio-pharma-stock-trading-higher-on-friday" rel="noreferrer noopener">Society of Cardiology 2024</a>.
Price Action: BBIO stock is up 2.39% at $25.54 at last check Monday.
Photo vis Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/24/09/41098199/ftc-clears-chevrons-53b-hess-merger-sets-restriction-for-john-hess" target="_blank" rel="noreferrer noopener">FTC Clears Chevron&#8217;s $53B Hess Merger, Sets Restriction For John Hess</a>.</li>
</ul>

Biotech

Equities

Movers

BBIO

BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease

RBC Capital analyst Walter Spracklin maintains Union Pacific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) with a Outperform and raises the price target from $275 to $288.

RBC Capital Maintains Outperform on Union Pacific, Raises Price Target to $288

In a 2021 segment on Money.com, finance guru <a href="https://www.benzinga.com/personal-finance/24/09/40950245/suze-orman-says-missing-this-one-crucial-monthly-payment-could-cost-you-big-heres-the-first-bill">Suze Orman tackled</a> various real-life financial questions, giving her signature "approved" or "denied" stamp on viewers' dreams. One scenario involved a 46-year-old woman asking if she could afford to take a year off work to travel on a budget of $40,000. Spoiler alert: Orman approved, but not without adding a healthy dose of financial wisdom.
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li>Can you guess how many retire with a $5,000,000 nest egg? &#8211;<a href="https://www.benzinga.com/money/retire-5mil-nest-egg"> How does it compare to the average?</a></li>
</ul>
The Scenario
The caller, who's doing pretty well financially, has a monthly income of $3,583 and zero debt. She's got $40,000 in liquid cash and $720,000 in her retirement account, and she plans to sell some stocks to fund her travels. In addition, she intends to rent out her home short-term to generate extra income while she's away.
Orman gave her the green light to take the trip, applauding her <a href="https://www.benzinga.com/personal-finance/24/09/40963028/suze-orman-says-keep-your-car-for-15-years-or-longer-instead-of-leasing-a-new-one-every-3-years-">smart financial planning</a>. But she didn't let her off the hook without a reality check about what that $40,000 could mean for her future.
<hr class="wp-block-separator has-alpha-channel-opacity" />
Trending: Founder of Personal Capital and ex-CEO of PayPal<a href="https://www.benzinga.com/money/evergreen-money"> re-engineers traditional banking with this new high-yield account — start saving better today.</a>
<hr class="wp-block-separator has-alpha-channel-opacity" />
$40,000 Today vs. $500,000 Tomorrow
Orman dropped a financial bombshell by pointing out that if $40,000 today were invested wisely, it could be worth half a million dollars 30 years from now. But how does that work?
Here's the math behind Orman's statement: Assuming an average annual return of 8% in a retirement account, $40,000 could grow to over $500,000 in 30 years due to the magic of compound interest. It's a reminder that today's spending comes with an opportunity cost – what you spend now won't have a <a href="https://www.benzinga.com/personal-finance/24/09/40971492/how-does-your-retirement-savings-compare-to-the-average-upper-class-nest-egg-heres-what-the-top-">chance to grow for your future</a>.
Orman's message was clear: while enjoying life now is important, balance that with planning for the future. The key is to find a way to enjoy experiences without jeopardizing long-term financial stability.
See Also: <a href="https://www.benzinga.com/money/irs-finalizes-10-year-rule-adv">IRS Finalizes 10-Year Rule For Retirement Withdrawals, Making Things &#8216;Even More Insanely Complicated&#8217;</a>
Retirement Tips: The Balancing Act
Suze Orman is famous for telling people to prioritize their retirement savings – and for good reason. People are living longer, and health care costs in retirement can be astronomical. For someone like the caller, who already has $720,000 saved, she's in a good spot. However, it's crucial to continue <a href="https://www.benzinga.com/personal-finance/24/07/40076189/suze-orman-says-youre-retired-your-portfolio-isnt-heres-her-advice-for-growing-your-nest-egg-in-">building that nest egg</a>.
Some tips for anyone considering a major life change like taking a year off include:
<ul>
<li>Maximize retirement contributions: This should be the first step if you're not already maxing out your 401(k) or IRA. The more you contribute now, the more time your investments have to grow.</li>
</ul>
<ul>
<li>Create multiple income streams: The caller&#8217;s decision to rent out her home was smart. Diversifying income sources like this can help cover travel expenses without dipping into savings.</li>
</ul>
<ul>
<li>Stay insured: Taking time off from work might mean losing employer-provided benefits like health insurance. Make sure to account for that in your budget.</li>
</ul>
<hr class="wp-block-separator has-alpha-channel-opacity" />
Trending: How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.
<hr class="wp-block-separator has-alpha-channel-opacity" />
Enjoy Today, Plan for Tomorrow
Orman's advice boils down to finding balance. If you're in a solid financial position, like the caller, and you've planned carefully, it's okay to splurge on life experiences. As Orman said, "Girlfriend, have the best time of your life!" Just don't forget about your future self while you're out there living in the moment.
Orman's approval came with a blend of excitement and caution, proving once again that it's possible to <a href="https://www.benzinga.com/money/can-you-guess-how-many-americans-successfully-retire-with-1-million-saved">enjoy today without sacrificing tomorrow</a>. After all, $40,000 may not seem like a lot now, but in 30 years, it could be the difference between working in your 70s or sipping cocktails on a beach in retirement.
Read Next:
A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> you can become part of the next big real estate boom today.</a>
These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a>

Personal Finance

46-Year-Old Making $3,583 A Month Asks Suze Orman If She Can Afford A Year Off To Travel – Orman Warns It'll Cost Her $500,000 In Retirement

Dyne Therapeutics's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NYSE">DYN</a>) short percent of float has risen 11.55% since its last report. The company recently reported that it has 7.66 million shares sold short, which is 9.08% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.76 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Dyne Therapeutics Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727716523_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Dyne Therapeutics has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Dyne Therapeutics's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Dyne Therapeutics's peer group average for short interest as a percentage of float is 15.27%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Dyne Therapeutics's Recent Short Interest

There's a lot to be optimistic about in the Consumer Goods sector as 2 analysts just weighed in on US Foods Holding (USFD – Research Report) and Su...

Analysts Offer Insights on Consumer Goods Companies: US Foods Holding (USFD) and SunOpta (STKL)

US Foods announces $211M share repurchase from Sachem Head Capital

Performance Food Group: Big Moves And Big Upside Does Not Justify Further Moves Higher

The food industry is expected to remain resilient due to constant demand, adaptability to consumer trends, and innovations in technology and supply chains, ensuring stability amid economic fluctuations. Therefore, investors looking for consistent returns might consider buying fundamentally strong food stocks such as US Foods Holding (USFD), and Sysco (SYY). Read on... The food industry is stable and growing, fueled by changing consumer preferences, sustainability trends, increased online sales, and rising demand for local, organic, and convenience-based products. Given this backdrop, investing in fundamentally strong food stocks like US Foods Holding Corp. (<a href="https://stocknews.com/stock/USFD/">USFD</a>) and Sysco Corporation (<a href="https://stocknews.com/stock/SYY/">SYY</a>) could be wise for consistent returns.
Despite geopolitical uncertainties and supply chain disruptions, rising incomes, a growing population, and technological advancements in food processing, innovative distribution, and automation boost the resilience of the food industry. This makes it a strong investment opportunity for stable returns. The food market's output is projected to reach $3.70 trillion in 2024, and grow at an <a href="https://www.statista.com/outlook/io/manufacturing/consumer-goods/food/worldwide#:~:text=Output%20in%20the%20Food%20market,amount%20to%203.9%25%20in%202024.">1.1% CAGR</a> from 2024 to 2029.
In addition, marketing in the food industry drives revenue through digital strategies like social media engagement, influencer partnerships, personalized content, and e-commerce optimization. Similarly, data analytics enhance brand visibility and customer loyalty, boosting sales and market growth. Hence, the U.S. food market is projected to generate <a href="https://www.statista.com/outlook/cmo/food/united-states">$833.80 billion in 2024</a>, with an expected annual growth rate of 4.1%.
Given this favorable backdrop, let's take a closer look at the fundamentals of the two featured <a href="https://stocknews.com/category/food-makers/">Food Makers</a> stocks, beginning with the second choice.
Stock #2: US Foods Holding Corp. (<a href="https://stocknews.com/stock/USFD/">USFD</a>)
USFD engages in the marketing, sale, and distribution of fresh, frozen, and dry food and non-food products to food service customers in the United States. The company's customers include independently owned single and multi-unit restaurants, national restaurant chains, hospitals, hotels and motels, country clubs, government and military organizations, colleges and universities, and retail locations.
In terms of forward EV/EBIT, USFD's 14.13x is 4.5% lower than the 14.80x industry average. Its 0.95x forward non-GAAP <a href="https://www.investopedia.com/terms/p/pegratio.asp">PEG</a> is 55.7% lower than the 2.14x industry average. Similarly, its 10.85x forward EV/EBITDA is marginally lower than the 10.88x industry average.
During the second quarter ended June 29, 2024, USFD's net sales grew 7.7% year-over-year to $9.71 billion. The company's adjusted gross profit increased 8.2% from the year-ago value to $1.71 billion. Likewise, its adjusted EBITDA rose 13.2% from the prior year's period to $489 million.
For the same period, its operating income was $353 million, up 9.6% from the prior-year quarter. Moreover, USFD's adjusted net income and adjusted EPS rose 16.1% and 17.7% from the year-ago value to $231 million and $0.93, respectively.
Street expects USFD's EPS and revenue for the quarter ended September 30, 2024, to increase 18.9% and 6.8% year-over-year to $0.83 and $9.72 billion, respectively. Over the past year, the stock has gained 45.7% to close the last trading session at $58.48.
USFD's positive outlook is reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. It has an overall rating of B, translating to a Buy in our proprietary rating system. The POWR ratings assess stocks by 118 different factors, each with its own weighting.
It has an A grade for Growth and a B for Value. It is ranked #16 out of 74 stocks in the B-rated <a href="https://stocknews.com/category/food-makers/">Food Makers</a> industry. To see USFD's Momentum, Stability, Sentiment, and Quality ratings, <a href="https://stocknews.com/stock/USFD/">click here</a>.
Stock #1: Sysco Corporation (<a href="https://stocknews.com/stock/SYY/">SYY</a>)
SYY and its subsidiaries engage in the marketing and distribution of various food and related products to the food service or food-away-from-home industry internationally. It operates through U.S. Foodservice Operations, International Foodservice Operations, SYGMA, and Other segments.
In terms of forward EV/Sales, SYY's 0.61x is 65.5% lower than the 1.78x industry average. Its 13.64x forward EV/EBIT is 7.9% lower than the 14.80x industry average. Likewise, its 16.86x forward non-GAAP P/E is 5.6% lower than the 17.86x industry average.
SYY's sales for the fiscal second quarter ended June 29, 2024, grew 4.2% year-over-year to $20.56 billion. The company's non-GAAP operating income was $1.08 billion, up 6.4% from the year-ago value. In addition, its non-GAAP net earnings increased 1.5% from the previous year's quarter to $693 million, and non-GAAP earnings per share rose 3.7% year-over-year to $1.39.
For the quarter ending September 30, 2024, SYY's EPS and revenue are expected to increase 5.7% and 4.4% year-over-year to $1.13 and $20.48 billion, respectively. It surpassed the consensus EPS estimates in each of the trailing four quarters. The stock has gained 9.9% over the past year to close the last trading session at $77.14.
It's no surprise that SYY has an overall rating of B, which translates to a Buy in our POWR Ratings system.
It has a B grade for Value, Stability, and Quality. It is ranked #13 in the Food Makers industry. To access the additional ratings of SYY for Growth, Momentum, and Sentiment, <a href="https://stocknews.com/stock/SYY/">click here</a>.
What To Do Next?
Discover 10 widely held stocks that our proprietary model shows have tremendous downside potential. Please make sure none of these "death trap" stocks are lurking in your portfolio:
<a href="https://report.stocknews.com/free-report/10-stocks-to-sell/?formplacement=artbotad_10sell">10 Stocks to SELL NOW! &gt;</a>

<hr />
SYY shares were trading at $77.16 per share on Friday afternoon, down $0.42 (-0.54%). Year-to-date, SYY has gained 7.67%, versus a 18.73% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Abhishek Bhuyan</h2> <img src='https:/wp-content/uploads/2023/07/ABhuyan.jpg' style="float:left; padding:5px;width:125px;">Abhishek embarked on his professional journey as a financial journalist due to his keen interest in discerning the fundamental factors that influence the future performance of financial instruments.<a href="https://stocknews.com/authors/?author=abhishek-bhuyan">More...</a>The post <a href=https://stocknews.com/news/syy-usfd-2-food-stocks-to-buy-for-consistent-returns/>2 Food Stocks to Buy for Consistent Returns</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

2 Food Stocks to Buy for Consistent Returns

The Chefs' Warehouse: Shares Are Undervalued, With Revenue Growth And Profitability

Food supplier stocks dip after Sysco warns on current trends

In a report released today, Alexander Slagle from Jefferies maintained a Buy rating on US Foods Holding (USFD – Research Report), with a price targ...

Comments

US Foods Hldg

Actualités

Dernières nouvelles pour US Foods Hldg (NYSE:USFD) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL